Please login to the form below
alpharadin
This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.
FDA clears Bayer/ Algeta's prostate cancer radiotherapy
Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up
Latest news
-
Bayer pins hopes on five potential blockbusters
Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched
-
FDA fast-tracks Bayer's prostate cancer radiotherapy
Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review
-
Bayer points to four blockbusters in portfolio
Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.
-
Bayer's prostate cancer drug fast-tracked
Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- New medical communications agency BOLDSCIENCE launches
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- 20 for 2020 – Five pharma companies to watch
- Shionogi's Gram-negative antibiotic launches in the UK
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
